Ardelyx Yönetim

Yönetim kriter kontrolleri 2/4

Ardelyx CEO'su Mike Raab, Mar2009 tarihinde atandı, in görev süresi 15.67 yıldır. in toplam yıllık tazminatı $ 4.12M olup, şirket hissesi ve opsiyonları dahil olmak üzere 17% maaş ve 83% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.52% ine doğrudan sahiptir ve bu hisseler € 5.29M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.2 yıl ve 9.1 yıldır.

Anahtar bilgiler

Mike Raab

İcra Kurulu Başkanı

US$4.1m

Toplam tazminat

CEO maaş yüzdesi	17.0%
CEO görev süresi	15.7yrs
CEO sahipliği	0.5%
Yönetim ortalama görev süresi	4.2yrs
Yönetim Kurulu ortalama görev süresi	9.1yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Mike Raab'un ücretlendirmesi Ardelyx'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$73m
Jun 30 2024	n/a	n/a	-US$65m
Mar 31 2024	n/a	n/a	-US$66m
Dec 31 2023	US$4m	US$700k	-US$66m
Sep 30 2023	n/a	n/a	-US$27m
Jun 30 2023	n/a	n/a	-US$56m
Mar 31 2023	n/a	n/a	-US$66m
Dec 31 2022	US$2m	US$650k	-US$67m
Sep 30 2022	n/a	n/a	-US$114m
Jun 30 2022	n/a	n/a	-US$135m
Mar 31 2022	n/a	n/a	-US$153m
Dec 31 2021	US$4m	US$650k	-US$158m
Sep 30 2021	n/a	n/a	-US$151m
Jun 30 2021	n/a	n/a	-US$125m
Mar 31 2021	n/a	n/a	-US$105m
Dec 31 2020	US$4m	US$633k	-US$94m
Sep 30 2020	n/a	n/a	-US$85m
Jun 30 2020	n/a	n/a	-US$91m
Mar 31 2020	n/a	n/a	-US$91m
Dec 31 2019	US$2m	US$595k	-US$95m
Sep 30 2019	n/a	n/a	-US$103m
Jun 30 2019	n/a	n/a	-US$104m
Mar 31 2019	n/a	n/a	-US$100m
Dec 31 2018	US$4m	US$575k	-US$91m
Sep 30 2018	n/a	n/a	-US$53m
Jun 30 2018	n/a	n/a	-US$50m
Mar 31 2018	n/a	n/a	-US$53m
Dec 31 2017	US$5m	US$555k	-US$64m

Tazminat ve Piyasa: Mike 'nin toplam tazminatı ($USD 4.12M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.41M ).

Tazminat ve Kazançlar: Mike şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Mike Raab (59 yo)

15.7yrs

Görev süresi

US$4,118,144

Tazminat

Mr. Michael G. Raab, also known as Mike, has been the Chief Executive Officer and President of Ardelyx, Inc. since March 2009. He is a Director of Tempest Therapeutics Inc. since May 2019 and its Chairman...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Raab	President	15.7yrs	US$4.12m	0.52% € 5.3m
Elizabeth Grammer	Chief Legal & Administrative Officer and Secretary	10.5yrs	US$1.63m	0.081% € 823.4k
Laura Williams	Chief Medical Officer	4yrs	US$1.63m	0.13% € 1.3m
Justin Renz	Chief Financial & Operations Officer	4.4yrs	US$1.73m	0.12% € 1.3m
Robert Felsch	Senior VP of Finance & Chief Accounting Officer	2.7yrs	Veri yok	0.039% € 391.9k
Caitlin Lowie	Vice President of Corporate Communications & Investor Relations	no data	Veri yok	Veri yok
Mike Kelliher	Executive Vice President of Corporate Development & Strategy	less than a year	Veri yok	Veri yok
Charon Spencer	Chief Human Resources Officer	1.8yrs	Veri yok	Veri yok
David Rosenbaum	Chief Development Officer	9.8yrs	US$1.63m	0.23% € 2.3m
Robert Blanks	Chief Regulatory Affairs & Quality Assurance Officer	no data	US$1.70m	0.13% € 1.4m
Susan Rodriguez	Advisor	4.5yrs	US$1.04m	0.19% € 1.9m
Eric Foster	Chief Commercial Officer	less than a year	Veri yok	Veri yok

4.2yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim: 41X 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Raab	President	15.7yrs	US$4.12m	0.52% € 5.3m
David Mott	Independent Chairman of the Board	15.7yrs	US$249.90k	0.51% € 5.2m
William C. Bertrand	Independent Director	9.1yrs	US$214.90k	0.097% € 983.5k
Richard Rodgers	Independent Director	10.7yrs	US$222.40k	0.11% € 1.1m
Robert Bazemore	Independent Director	8.4yrs	US$202.40k	Veri yok
Onaiza Cadoret-Manier	Independent Director	4.7yrs	US$199.90k	0.047% € 471.5k
Muna Bhanji	Independent Director	3.7yrs	US$202.40k	0.040% € 410.1k

9.1yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 41X 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.1 yıldır).

Ardelyx Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Ardelyx, Inc. Appoints Eric Foster as Chief Commercial Officer

Chief Medical Officer recently sold €295k worth of stock

Ardelyx, Inc. Announces Rodriguez Would Resign as Chief Commercial Officer

President recently sold €226k worth of stock

Insider recently sold €726k worth of stock

Ardelyx, Inc., Annual General Meeting, Jun 14, 2024

Recent updates

New minor risk - Shareholder dilution

Third quarter 2024 earnings released: US$0.003 loss per share (vs US$0.03 profit in 3Q 2023)

Ardelyx, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Ardelyx, Inc. to Present Additional Data Supporting First-In-Class XPHOZAH (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology's Kidney Week

Ardelyx, Inc. Announces Publication of A Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology

Robbins LLP Informs Ardelyx, Inc. Stockholders of the Class Action

Ardelyx, Inc. Appoints Eric Foster as Chief Commercial Officer

Second quarter 2024 earnings released: US$0.07 loss per share (vs US$0.08 loss in 2Q 2023)

Forecast breakeven date moved forward to 2025

Ardelyx, Inc. Announces Publication of Two Plain Language Summaries from XPHOZAH®? (tenapanor) Clinical Trials in Current Medical Research and Opinion

Ardelyx, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Forecast breakeven date pushed back to 2026

Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell Small Cap Comp Value Index

Ardelyx, Inc. Chooses Not to File for TDAPA to Preserve Patient Access to XPHOZAH

Chief Medical Officer recently sold €295k worth of stock

Ardelyx, Inc. Announces Rodriguez Would Resign as Chief Commercial Officer

President recently sold €226k worth of stock

Insider recently sold €726k worth of stock

Forecast breakeven date pushed back to 2026

First quarter 2024 earnings released: US$0.11 loss per share (vs US$0.13 loss in 1Q 2023)

Ardelyx, Inc., Annual General Meeting, Jun 14, 2024

Ardelyx, Inc. to Report Q1, 2024 Results on May 02, 2024

Ardelyx, Inc. Announces the Appointment of Mike Kelliher as Executive Vice President, Corporate Development and Strategy

Ardelyx, Inc. announced that it has received $50 million in funding

Full year 2023 earnings released: US$0.30 loss per share (vs US$0.42 loss in FY 2022)

Ardelyx, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Ardelyx Announces Departure of Geoffrey Block as Board Member

Ardelyx, Inc. Announces XPHOZAH(R) (tenapanor) Now Available in the United States

Ardelyx Shares Positive Data from Studies of Xphozah®? (Tenapanor) At Asn Kidney Week 2023

Ardelyx, Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$0.03 (vs US$0.14 loss in 3Q 2022)

Ardelyx, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Insufficient new directors

Ardelyx, Inc. Shares Positive Data on Symptom Response During Treatment with IBSRELA®? (tenapanor) for IBS-C and Hosts IBS-C Product Theater at ACG 2023

Ardelyx, Inc. Announces FDA Approval of XPHOZAH (tenapanor), a First-In-Class Phosphate Absorption Inhibitor

Ardelyx, Inc. Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

New major risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.08 loss per share (vs US$0.18 loss in 2Q 2022)

Ardelyx, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Forecast breakeven date pushed back to 2025

Ardelyx, Inc. Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH(R)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.21 loss in 1Q 2022)

Full year 2022 earnings released: US$0.42 loss per share (vs US$1.52 loss in FY 2021)

FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)

Forecast to breakeven in 2024

Ardelyx Provides Update on FDA Appeal for XPHOZAH (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

High number of new directors

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.42 loss in 3Q 2021)

Ardelyx Presents New Data Analyses At Kidney Week 2022, Further Supporting the Clinical Relevance of Xphozah(R) (Tenapanor)

Ardelyx, Inc Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan

Ardelyx, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Ardelyx, Inc. to Present Poster Presentations on IBSRELA (Tenapanor) for Adult Patients with IBS-C At the American College of Gastroenterology 2022 Annual Scientific Meeting

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.45 loss in 2Q 2021)

President recently sold €63k worth of stock

Ardelyx Receives Letter from the Nasdaq Global Market

First quarter 2022 earnings released: US$0.21 loss per share (vs US$0.34 loss in 1Q 2021)

Ardelyx, Inc., Annual General Meeting, Jun 15, 2022

High number of new directors

Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH(R) (tenapanor)

Ardelyx, Inc. Completes Three Successful Phase 3 Pivotal Trials, and Two Additional Phase 4 Clinical Trials (OPTIMIZE and NORMALIZE) for XPHOZAH

Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Ardelyx, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Ardelyx, Inc. Receives an Appeal Denied Letter from the Office of Cardiology, Hematology, Endocrinology and Nephrology of the U.S. Food and Drug Administration

Ardelyx Announces Launching of IBSRELA® Second Quarter of 2022

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.20 loss in 3Q 2020)

Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial

Second quarter 2021 earnings released: US$0.45 loss per share (vs US$0.28 loss in 2Q 2020)